NOVARTIS PHARMACEUTICALS CORPORATION

Novartis Pharmaceuticals Corporation specializes in the manufacturing and supply of advanced pharmaceutical preparations, with a demonstrated focus on radiopharmaceuticals and targeted therapies for specialized patient populations. The contractor’s core capabilities center on the production and distribution of complex, FDA-approved therapeutics such as Pluvicto (lutetium Lu 177 vipivotide tetraxetan) and Fabhalta (avacopan), indicating deep expertise in radioligand therapy, small molecule formulation, and oncology-focused drug manufacturing. Their technical proficiency spans GMP-compliant production processes, supply chain logistics for controlled substances, and regulatory adherence for specialty pharmaceuticals, positioning them as a reliable provider of high-complexity, low-volume therapeutics critical to chronic and rare disease management. The contractor maintains a consistent relationship with the Department of Veterans Affairs, supplying specialty medications through long-term procurement arrangements, suggesting a trusted vendor status within VA’s national pharmaceutical distribution network. Additional engagements with the Defense Health Agency and NETWORK Contract Offices indicate participation in defense and federal healthcare supply chains, primarily for oncology and immunology therapeutics requiring stringent cold-chain handling and controlled distribution protocols. The primary NAICS code 325412 reflects core activity in pharmaceutical preparation manufacturing, with a clear vertical specialization in oncology, rare disease, and targeted radiopharmaceuticals. The contractor’s market positioning is defined by its ability to deliver complex, clinically critical drugs under strict regulatory oversight, serving government health systems that require assured access to innovative, high-cost therapies. As a 2L entity headquartered in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation operates as a large-scale pharmaceutical manufacturer with established federal procurement infrastructure. While no government-specific certifications are listed, its consistent award history implies robust compliance with federal pharmaceutical sourcing standards, including cGMP, DEA controls, and DOD/VA contract requirements. The company’s geographic presence is anchored in the U.S. biopharmaceutical corridor, supporting nationwide government healthcare delivery networks.